Research programme: human monoclonal antibodies - Athersys/Medarex

Drug Profile

Research programme: human monoclonal antibodies - Athersys/Medarex

Alternative Names: Human monoclonal antibodies research programme - Athersys/Medarex

Latest Information Update: 20 Mar 2007

Price : $50

At a glance

  • Originator Athersys; Medarex
  • Class Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 20 Mar 2007 No development reported - Preclinical for Cancer in USA (unspecified route)
  • 02 Jul 2002 This programme is still in active development
  • 24 Aug 2000 Preclinical development for Cancer in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top